Back to News
Market Impact: 0.4
Tarsus Pharmaceuticals, Inc. Reports Record XDEMVY Net Product Sales of $194.6 million in Third Quarter 2026
Source: Nasdaq
Corporate EarningsHealthcare & BiotechCompany FundamentalsProduct Launches
Tarsus Pharmaceuticals reported record XDEMVY net product sales of $194.6 million for the third quarter ended September 30, 2026, up approximately 64% year over year from $118.7 million. The provided article text contains no further results or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
TARS0.75
More News
- NextDC shares surge 43% after Goodman, Digital Realty stake purchases
- Qualcomm issues disappointing earnings forecast as memory shortage weighs on smartphone sales
- ‘Seismic’ blue wave triggers the sinking of oil prices, energy stocks, and the chances of power permitting reform
- Softbank’s $5.4 bln takeover of ABB robotics unit blocked by China- FT
- Nifty Bounces Back to Beat All of Asia on Foreign Flows, Earnings
- Snap shares fall over 10% on third-quarter earnings miss